Atorvastatin-mediated Rescue of Cancer-related Cognitive Changes in Combined Anticancer Therapies

Overview

Journal PLoS Comput Biol

Specialty Biology

Date 2021 Oct 20

PMID 34669701

Citations 2

Authors

Junho Lee

Jin Su Kim

Yangjin Kim

Affiliations

Soon will be listed here.

Abstract

Acute administration of trastuzumab (TZB) may induce various forms of cognitive impairment. These cancer-related cognitive changes (CRCC) are regulated by an adverse biological process involving cancer stem cells (CSCs) and IL-6. Recent studies have reported that atorvastatin (ATV) may change the dynamic of cognitive impairment in a combination (TZB+ATV) therapy. In this study, we investigate the mutual interactions between cancer stem cells and the tumor cells that facilitate cognitive impairment during long term TZB therapy by developing a mathematical model that involves IL-6 and the key apoptotic regulation. These include the densities of tumor cells and CSCs, and the concentrations of intracellular signaling molecules (NFκB, Bcl-2, BAX). We apply the mathematical model to a single or combination (ATV+TZB) therapy used in the experiments to demonstrate that the CSCs can enhance CRCC by secreting IL-6 and ATV may interfere the whole regulation. We show that the model can both reproduce the major experimental observation on onset and prevention of CRCC, and suggest several important predictions to guide future experiments with the goal of the development of new anti-tumor and anti-CRCC strategies. Moreover, using this model, we investigate the fundamental mechanism of onset of cognitive impairment in TZB-treated patients and the impact of alternating therapies on the anti-tumor efficacy and intracellular response to different treatment schedules.

Citing Articles

Nanotechnology Approaches for Prevention and Treatment of Chemotherapy-Induced Neurotoxicity, Neuropathy, and Cardiomyopathy in Breast and Ovarian Cancer Survivors.

Nevins S, McLoughlin C, Oliveros A, Stein J, Rashid M, Hou Y Small. 2023; 20(41):e2300744.

PMID: 37058079 PMC: 10576016. DOI: 10.1002/smll.202300744.

Enhancement of the anticancer effect of atorvastatin-loaded nanoemulsions by improving oral absorption via multivalent intestinal transporter-targeting lipids.

Subedi L, Pandey P, Khadka B, Shim J, Cho S, Kweon S Drug Deliv. 2022; 29(1):3397-3413.

PMID: 36419245 PMC: 9704079. DOI: 10.1080/10717544.2022.2149896.

References

Erickson M, Banks W . Neuroimmune Axes of the Blood-Brain Barriers and Blood-Brain Interfaces: Bases for Physiological Regulation, Disease States, and Pharmacological Interventions. Pharmacol Rev. 2018; 70(2):278-314. PMC: 5833009. DOI: 10.1124/pr.117.014647. View

Tindall M, Clerk A . Modelling negative feedback networks for activating transcription factor 3 predicts a dominant role for miRNAs in immediate early gene regulation. PLoS Comput Biol. 2014; 10(5):e1003597. PMC: 4014390. DOI: 10.1371/journal.pcbi.1003597. View

Horowitz T, Suls J, Trevino M . A Call for a Neuroscience Approach to Cancer-Related Cognitive Impairment. Trends Neurosci. 2018; 41(8):493-496. DOI: 10.1016/j.tins.2018.05.001. View

Bergqvist S, Ghosh G, Komives E . The IkappaBalpha/NF-kappaB complex has two hot spots, one at either end of the interface. Protein Sci. 2008; 17(12):2051-8. PMC: 2590914. DOI: 10.1110/ps.037481.108. View

Westphal D, Kluck R, Dewson G . Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis. Cell Death Differ. 2013; 21(2):196-205. PMC: 3890949. DOI: 10.1038/cdd.2013.139. View

Baselga J, Albanell J . Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol. 2001; 12 Suppl 1:S35-41. DOI: 10.1093/annonc/12.suppl_1.s35. View

Richardson P, Hideshima T, Anderson K . Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control. 2003; 10(5):361-9. DOI: 10.1177/107327480301000502. View

Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T . The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med. 1989; 169(1):333-8. PMC: 2189201. DOI: 10.1084/jem.169.1.333. View

Godlewski J, Nowicki M, Bronisz A, Nuovo G, Palatini J, De Lay M . MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell. 2010; 37(5):620-32. PMC: 3125113. DOI: 10.1016/j.molcel.2010.02.018. View

10.

Henderson F, Cross A, Baraniak A . 'A new normal with chemobrain': Experiences of the impact of chemotherapy-related cognitive deficits in long-term breast cancer survivors. Health Psychol Open. 2019; 6(1):2055102919832234. PMC: 6405778. DOI: 10.1177/2055102919832234. View

11.

Aguda B, Kim Y, Piper-Hunter M, Friedman A, Marsh C . MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc. Proc Natl Acad Sci U S A. 2008; 105(50):19678-83. PMC: 2598727. DOI: 10.1073/pnas.0811166106. View

12.

Martins W, Dos Santos V, Dos Santos A, Vandresen-Filho S, Dal-Cim T, de Oliveira K . Atorvastatin Prevents Cognitive Deficits Induced by Intracerebroventricular Amyloid-β1-40 Administration in Mice: Involvement of Glutamatergic and Antioxidant Systems. Neurotox Res. 2015; 28(1):32-42. DOI: 10.1007/s12640-015-9527-y. View

13.

de Los Reyes V A, Jung E, Kim Y . Optimal control strategies of eradicating invisible glioblastoma cells after conventional surgery. J R Soc Interface. 2015; 12(106). PMC: 4424672. DOI: 10.1098/rsif.2014.1392. View

14.

Lytle N, Barber A, Reya T . Stem cell fate in cancer growth, progression and therapy resistance. Nat Rev Cancer. 2018; 18(11):669-680. PMC: 8388042. DOI: 10.1038/s41568-018-0056-x. View

15.

Hsu E, Kulp S, Huang H, Tu H, Chao M, Tseng Y . Integrin-linked kinase as a novel molecular switch of the IL-6-NF-κB signaling loop in breast cancer. Carcinogenesis. 2016; 37(4):430-442. PMC: 5006214. DOI: 10.1093/carcin/bgw020. View

16.

Terrell-Hall T, Nounou M, El-Amrawy F, Griffith J, Lockman P . Trastuzumab distribution in an and model of brain metastases of breast cancer. Oncotarget. 2017; 8(48):83734-83744. PMC: 5663550. DOI: 10.18632/oncotarget.19634. View

17.

Aspirin A, de Los Reyes V A, Kim Y . Polytherapeutic strategies with oncolytic virus-bortezomib and adjuvant NK cells in cancer treatment. J R Soc Interface. 2021; 18(174):20200669. PMC: 7879760. DOI: 10.1098/rsif.2020.0669. View

18.

Thongtang N, Diffenderfer M, Ooi E, Asztalos B, Dolnikowski G, Lamon-Fava S . Effects of atorvastatin on human C-reactive protein metabolism. Atherosclerosis. 2012; 226(2):466-70. PMC: 5489069. DOI: 10.1016/j.atherosclerosis.2012.11.012. View

19.

Kesler S, Hosseini S, Heckler C, Janelsins M, Palesh O, Mustian K . Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors. Clin Breast Cancer. 2013; 13(4):299-306. PMC: 3726272. DOI: 10.1016/j.clbc.2013.02.004. View

20.

Wong D, Hurvitz S . Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. Ann Transl Med. 2015; 2(12):122. PMC: 4260046. DOI: 10.3978/j.issn.2305-5839.2014.08.13. View